Novartis Head Of Pharma Development James Shannon: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is moving forward with a new drug development paradigm and its “category captainship” program.
You may also be interested in...
CRO Work Flow Shifts To More Early-Stage Studies, Covance CEO Says
Industry could see further growth as pharma and biotech companies reassess the drug development paradigm.
CRO Work Flow Shifts To More Early-Stage Studies, Covance CEO Says
Industry could see further growth as pharma and biotech companies reassess the drug development paradigm.
Novartis Seeks European Approval For Galvus
The novel type 2 diabetes therapy has a likely November user fee date in the U.S.